Table 1

Association among MNSI, individual components of diabetic polyneuropathy, and immunological variables (multivariable-adjusted analysis)

Dependent variableModel 1
Model 2
Model 3
Model 4
βPβPβPβP
MNSI score
    CRP (mg/l)0.170.00050.140.00430.140.00550.140.0067
    IL-6 (pg/ml)0.090.00150.080.00820.080.00900.080.0076
    IL-18 (pg/ml)−0.030.13−0.030.15−0.030.094−0.030.11
Ankle reflex score
    CRP (mg/l)0.140.00370.100.0600.090.0760.090.086
    IL-6 (pg/ml)0.080.00580.050.0800.050.0870.060.079
    IL-18 (pg/ml)−0.050.012−0.040.023−0.050.014−0.050.013
Vibration perception score
    CRP (mg/l)−0.010.075−0.0080.23−0.0080.23−0.0070.28
    IL-6 (pg/ml)−0.010.0036−0.0080.034−0.0080.031−0.0080.035
    IL-18 (pg/ml)0.0030.220.0020.340.0020.310.0030.26
Temperature perception score
    CRP (mg/l)−0.040.39−0.050.23−0.060.17−0.060.21
    IL-6 (pg/ml)−0.040.18−0.040.17−0.040.15−0.040.13
    IL-18 (pg/ml)0.010.350.020.220.020.250.020.31
Appearance of feet
    CRP (mg/l)0.390.0100.360.0190.340.0260.360.024
    IL-6 (pg/ml)0.200.0370.190.0410.190.0470.200.040
    IL-18 (pg/ml)0.030.650.010.85−0.0040.950.0040.94
Pain perception (pinprick)
    CRP (mg/l)0.110.550.0030.990.010.94−0.030.88
    IL-6 (pg/ml)0.250.0230.200.0820.200.0760.200.085
    IL-18 (pg/ml)−0.150.021−0.140.045−0.130.059−0.150.035
Pain or discomfort in the lower limbs
    CRP (mg/l)−0.060.74−0.040.79−0.050.76−0.110.52
    IL-6 (pg/ml)−0.060.59−0.060.53−0.060.55−0.070.53
    IL-18 (pg/ml)0.100.0950.110.0870.100.100.100.10
  • Regression coefficients β and P values for MNSI score and individual impairments are from multiple linear regression models with ln-transformed concentrations of immune mediators as dependent variables. Details on the assessment of neuropathic deficits are given in the online appendix. Model 1: adjusted for age and sex; model 2: adjustment for model 1 variables plus waist circumference, duration of diabetes, A1C, hypertension, and total cholesterol; model 3: adjustment for model 2 variables plus smoking, high alcohol intake, and physical activity; model 4: adjustment for model 3 variables plus lipid-lowering medication, nonsteroidal anti-inflammatory drugs, and recent respiratory infections.